E-LIB Suche - Ergebnisse für: Levis, Mark

1

Health-Related Quality of Life with Gilteritinib Versus Pla..:

Hamilton, Betty K. ; Levis, Mark J. ; Pandya, Bhavik J...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S44-S45 , 2024

Link: https://doi.org/10.1016/..

2

Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leuk..:

Zhu, Ruiqi ; Shirley, Courtney M. ; Chu, S. Haihua...
Leukemia. 38 (2024) 7 - p. 1581-1591 , 2024

Link: https://doi.org/10.1038/..

3

A phase 1 study of the irreversible FLT3 inhibitor FF-10101..:

Levis, Mark ; Perl, Alexander ; Schiller, Gary...
Blood Advances. 8 (2024) 10 - p. 2527-2535 , 2024

Link: https://doi.org/10.1182/..

4

POSTER: CT-186 Impact of Allogeneic Hematopoietic Cell Tran..:

Schlenk, Richard F. ; Montesinos, Pau ; Romero-Aguilar, Antonio...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S229 , 2023

Link: https://doi.org/10.1016/..

5

The clinical impact of the molecular landscape of acute mye..:

Kayser, Sabine ; Levis, Mark J.
Haematologica. 108 (2023) 2 - p. 308-320 , 2023

Link: https://doi.org/10.3324/..

6

AML-132 QuANTUM-First Trial: FLT3–Internal Tandem Duplicati..:

Levis, Mark J. ; Erba, Harry P. ; Montesinos, Pau...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S272 , 2023

Link: https://doi.org/10.1016/..

7

CT-186 Impact of Allogeneic Hematopoietic Cell Transplantat..:

Schlenk, Richard F. ; Montesinos, Pau ; Romero-Aguilar, Antonio...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S521-S522 , 2023

Link: https://doi.org/10.1016/..

8

An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiolog..:

Bystrom, Rebecca ; Levis, Mark J.
Current Oncology Reports. 25 (2023) 4 - p. 369-378 , 2023

Link: https://doi.org/10.1007/..

9

Oral Abstract: CT-186 Impact of Allogeneic Hematopoietic Ce..:

Schlenk, Richard F. ; Montesinos, Pau ; Romero-Aguilar, Antonio...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S148 , 2023

Link: https://doi.org/10.1016/..

10

Allogeneic Blood or Marrow Transplantation with High-Dose P..:

Webster, Jonathan A. ; Reed, Madison ; Tsai, Hua-Ling...
Transplantation and Cellular Therapy. 29 (2023) 3 - p. 182.e1-182.e8 , 2023

Link: https://doi.org/10.1016/..

11

P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RES..:

Levis, Mark J ; Erba, Harry P. ; Montesinos, Pau...
HemaSphere. 7 (2023) S3 - p. e446548f , 2023

Link: https://doi.org/10.1097/..

12

Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory..:

Perl, Alexander E. ; Larson, Richard A. ; Podoltsev, Nikolai A....
Transplantation and Cellular Therapy. 29 (2023) 4 - p. 265.e1-265.e10 , 2023

Link: https://doi.org/10.1016/..

13

Impact of inotuzumab ozogamicin on outcome in relapsed or r..:

Kayser, Sabine ; Sartor, Chiara ; Giglio, Fabio...
Haematologica. , 2023

Link: https://doi.org/10.3324/..

14

Outcome heterogeneity of TP53-mutated myeloid neoplasms and..:

Pasca, Sergiu ; Haldar, Saurav D. ; Ambinder, Alexander...
Haematologica. 109 (2023) 3 - p. 948-952 , 2023

Link: https://doi.org/10.3324/..

15

POSTER: AML-132 QuANTUM-First Trial: FLT3–Internal Tandem D..:

Levis, Mark J. ; Erba, Harry P. ; Montesinos, Pau...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S166 , 2023

Link: https://doi.org/10.1016/..